摘要
目的 ：系统评价肝病治疗仪对非酒精性脂肪性肝病的临床疗效和安全性。方法 ：通过计算机检索中国期刊全文数据库（CNKI）、中国生物医学文献数据库（CBM）、中文科技期刊全文数据库（VIP）、万方数据库、EMbase、Pub Med、The Cocharane Library,检索起止时间为建库至2015年8月,收集国内外有关肝病治疗仪治疗非酒精性脂肪性肝病的随机/半随机对照试验,采用Cochrane协作网推荐的方法进行文献质量评价,使用Rev Man 5.2软件进行Meta分析。结果 ：共纳入8篇文献,包括748例患者。Meta分析结果显示：单纯肝病治疗仪干预与未干预相比,除了肝脏酶学ALT[MD=-4.96,95%CI（-11.22,1.30）,P=0.12]方面无明显改善外,在总有效率[OR=5.83,95%CI（2.76,12.34）,P〈0.00001]、临床治愈率[OR=2.78,95%CI（1.34,5.77）,P=0.006]以及改善肝脏酶学AST[MD=-22.88,95%CI（-33.72,-12.04）,P〈0.0001],血脂TC[MD=-1.70,95%CI（-1.96,-1.44）,P〈0.00001]、TG[MD=-0.33,95%CI（-0.49,-0.17）,P〈0.0001],腹部彩超脂肪肝程度[总有效率：OR=7.45,95%CI（2.90,19.18）,P〈0.0001;临床痊愈：OR=4.06,95%CI（1.53,10.88）,P=0.005]等方面均有明显优势;而肝病治疗仪联合西药在总有效率[OR=5.15,95%CI（3.12,8.51）,P〈0.00001]、治愈率[OR=1.79,95%CI（1.79,4.05）,P〈0.00001]以及改善肝脏酶学ALT[MD=-10.88,95%CI（-13.84,-7.92）,P〈0.00001]、AST[MD=-15.67,95%CI（-18.24,-13.10）,P〈0.00001],血脂TC[MD=-1.51,95%CI（-2.18,-0.84）,P〈0.0001]及TG[MD=-0.70,95%CI（-1.16,-0.23）,P=0.003],腹部彩超脂肪肝程度[总有效率：OR=2.85,95%CI（1.52,5.34）,P=0.0001;临床痊愈：OR=3.27,95%CI（1.42,7.52）,P=0.005]等方面均优于单纯西药治疗。结论 ：肝病治疗仪对非酒精性脂肪性肝病有较好疗效,尚未见明显不良反应。但受纳入研究数量及质量所限,本结论仍需更多高质量及多中心的研究来验证。
Objective ：To systematically evaluate the efficacy and safety of liver disease therapy instrument for NAFLD. Methods ：Databases including CNKI,CBM,VIP,Wang Fang Data,EMbase,Pub Med,the Cocharane Library were searched to collect the RCTs and q RCTs of liver disease therapy instrument for NAFLD,the method recommended by the cochrane collaboration was applied to evaluate the quality of the studies and to conduct meta-analysis. Results ：8 studies involving 748 patients were included. The results of meta-analysis showed that ：compared with no intervention,simple liver disease treatment instrument in addition to hepatic enzymatic ALT no significant improvement [MD=-4.96,95%CI（-11.22,1.30）,P=0.12],in improving the total effective rate [OR=5.83,95%CI（2.76,12.34）,P〈0.00001],clinical cure rate [OR=2.78,95%CI（1.34,5.77）,P=0.006] and hepatic enzyme AST [MD=-22.88,95%CI（-33.72,-12.04）,P〈0.0001],lipid TC [MD=-1.70,95%CI（-1.96,-1.44）,P〈0.00001],lipid TG [MD=-0.33,95%CI（-0.49,-0.17）,P〈0.0001],abdominal ultrasound [the total effective rate ：OR=7.45,95%CI（2.90,19.18）,P〈0.0001;the clinical cure rate ：OR=4.06,95%CI（1.53,10.88）,P=0.005] had obvious advantages. The liver disease treatment instrument combined with western medicine in the total effective rate [OR=5.15,95%CI（3.12,8.51）,P〈0.00001],clinical cure rate [OR=1.79,95%CI（1.79,4.05）,P〈0.00001],the hepatic enzymes ALT and AST [MD=-10.88,95%CI（-13.84,-7.92）,P〈0.00001;MD=-15.67,95%CI（-18.24,-13.10）,P〈0.00001],lipids TC and TG [MD=-1.51,95%CI（-2.18,-0.84）,P〈0.0001;MD=-0.70,95%CI（-1.16,-0.23）,P=0.003],abdominal ultrasound [the total effective rate ：OR=2.85,95%CI（1.52,5.34）,P=0.0001;the clinical cure rate ：OR=3.27,95%CI（1.42,7.52）,P=0.005] were better than Western medicine alone. Conclusion ：The study shows that liver disease therapy instrument is superior to simple medicine and placebo in treating NAFLD,and has no serious adverse reactions. Due to the limited quantity and quality of t
出处
《辽宁中医药大学学报》
CAS
2018年第1期85-89,共5页
Journal of Liaoning University of Traditional Chinese Medicine
基金
北京大兴区科技发展计划项目(15048-1)
关键词
非酒精性脂肪性肝病
肝病治疗仪
系统评价
non alcoholic fatty liver disease
liver disease therapy instrument
systematic review
